As I was trying to answer to this side of the table, the volume of work has increased. We have 22 drugs of the 1,100 that are deemed to be non-compliant. This is more than in the past. There has been a trend towards relative non-compliance. You may say that 90% are compliant and that's really great. That's a reflection on the success of the regime, I might say, but there are more that are not compliant. There are various reasons out there for that.
In Canada, there are fewer breakthrough drugs being introduced, so the pharmaceutical companies, in order to improve their margins and so on, are creating incremental improvements for which they ask a higher price than our scientists, our staff, and our regulations feel is warranted. That's basically the issue of it. That's why we have the hearings.